Baseline Productions

Baseline Productions Change in Working Capital

The Change in Working Capital of Baseline Productions (BSSP) as of Nov 15, 2026 is 67,600.00 USD. In the previous year, Change in Working Capital was 68,200.00 USD — a change of -0.88% (lower).

Change in Working Capital

67,600.00USD

YoY

-0.88%

Last updated:

Change in Working Capital of Baseline Productions is 2020 67,600.00 USD. Change in Working Capital of Baseline Productions was 2019 68,200.00 USD. It decreases by -0.88% lower compared to the previous year.

The Baseline Productions Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2014
15,569.00 USD
Jan 1, 2019
68,200.00 USD
Jan 1, 2020
67,600.00 USD
The Baseline Productions Change in Working Capital history
YEARChange in Working CapitalYoY
67,600.00USD-0.88%
68,200.00USD+338.05%
15,569.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

Change in Working Capital of Baseline Productions is 67,600.00 USD in 2020.

Change in Working Capital of Baseline Productions changed from 68,200.00 USD to 67,600.00 USD, representing a -0.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Baseline Productions historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Baseline Productions

All Key Metrics — Baseline Productions